Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP Expert Panel Recommendations: Time for a new look at how to report heterogeneity

American Journal of Clinical Pathology

Volumn 136, Issue 6, 2011, Pages 864-871

  Allison, Kimberly H ^a   Dintzis, Suzanne M ^a   Schmidt, Rodney A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast cancer; CAP guidelines; Expert panel recommendations; FISH; Fluorescence in situ hybridization; HER2; Heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CELL HETEROGENEITY; CENTROMERE; CENTROMERE 17; CLINICAL PRACTICE; COLLEGE OF AMERICAN PATHOLOGIST; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PANEL STUDY; PATHOLOGIST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2;

EID: 82655171622     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPXTZSKBRIP07W     Document Type: Article

References (21)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
2. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611-612.
3. Hsu CY, Li AF, Yang CF, et al. Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer [letter]. Arch Pathol Lab Med. 2010;134:162.
4. Albarracin C, Edgerton ME, Gilcrease MZ, et al. Is it too soon to start reporting HER2 genetic heterogeneity [letter]? Arch Pathol Lab Med. 2010;134:162-163.
5. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134:284-292.
6. Paik S, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be continued to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31 [abstract]. J Clin Oncol. 2007;25(18 suppl). Abstract 511.
7. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358:1409-1411. (Pubitemid 351468442)
8. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol. 2005;124:273-281. (Pubitemid 41060140)
9. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007;16:207-210. (Pubitemid 350196977)
10. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol. 2011;136:266-274.
11. Malowany JI, MJ, Wood M, et al. Genetic heterogeneity in HER2 testing revisited: how nonuniform are "genetically heterogeneous" tumors? a study of 1550 HER2 FISH cases. USCAP 100th Annual Meeting edn, Vol. 24, Modern Pathology San Antonio, TX. 2011, p 53A.
12. Shafi H, MS, Bose S. HER2/neu Genetic heterogeneity (GH) in breast cancer as defined by CAP guidelines correlates with negative prognostic factors. USCAP 100th Annual Meeting edn, Vol. 24, Modern Pathology: San Antonio, TX. 2011, p63A.
13. Gunn S, Yeh I-T, Lytvak I, et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 2010;10:396. doi:10.1186/1471-2407-10-396.
14. Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009;22:1169-1175.
15. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? a fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009;219:16-24.
16. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clin Pathol. 2008;130:920-926.
17. Viale G. Be precise! the need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol. 2009;219:1-2.
18. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true HER-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 2006;5:2572-2579. (Pubitemid 44650922)
19. Kaufman PA, Broadwater G, Lezon-Geyda K, et al. CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2-metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2007;25(18 suppl). Abstract 1009.
20. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009;27:2962-2969.
21. Vranic S, Teruya B, Repertinger S, et al. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer. 2011;117:48-53.